source
- STAT+: Hospitals win the midterms, and Chopping Very StrategicallyWe explain the CVS breakup, and why Democrats' election victories are good news for hospitals.STAT · 21m ago↗ source
- Vir's hepatitis delta combo tamps down virus as Gilead showdown loomsVir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.BioSpace · 49m ago↗ source
- Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patientsAfter Novartis confirmed the reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy, the FDA will determine if any regulatory action is needed for Zolgens…